Chief Executive Officer of Somaxon Pharmaceuticals, Inc. (SOMX) Discusses Commercialization Strategy for Silenor® to Treat Insomnia
Source: http://Blog.QualityStocks.net/?p=12932Posted on Tuesday, October 14th, 2008 | In Small & Micro Cap
Somaxon Pharmaceuticals, Inc. (NASD: SOMX), a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, recently announced that the company’s president and chief executive officer, Richard Pascoe, presented earlier this week at the Natixis Bleichroeder second annual Hidden Gems Conference in New York, NY.
At the conference, Mr. Pascoe stated that Somaxon has completed four successful Phase 3 clinical trials for its lead product candidate, Silenor® (doxepin HCl) for the treatment of insomnia. In each of these clinical trials, Silenor® demonstrated statistically significant and clinically meaningful results in the designated primary endpoint and in several other important secondary endpoints. Somaxon expects that the FDA will complete its review and provide an action letter to the company with respect to the NDA by December 1, 2008.
Regarding the results of the Silenor® clinical trial, Mr. Pascoe stated, “There is a significant opportunity for a new drug like this to enter the market and gain substantial market share. Partnering is important and could happen at any time, but we are focused on getting this drug approved, building a commercial platform and launching the drug early next year. We will take the lead in terms of marketing this product.” Mr. Pasco added, “We have approximately $32 million cash available to us, and we continue to maintain that we will have a cash runway to us to take us through the first quarter.”
Let us hear your thoughts below:
Last 5 posts by QualityStocks
- View Systems (VSYM.OB) Up Almost 150% After Coverage by QualityStocks Newsletter - November 24th, 2009
- Consorteum Holdings, Inc. (CSRH.OB) Offers Right Source Solutions in the Payments and Transactions Industry - November 24th, 2009
- Some Options as the US Dollar Continues its Slide - November 24th, 2009
- Newport Digital Technologies (NPDT.OB) Has a Competitive Edge - November 24th, 2009
- Small Cap Voice Featured Company: DecisionPoint Systems, Inc. (DNPI.OB) - November 24th, 2009
Fda, insomnia, Nasd, New York, Pasco, Pharmaceutical, Richard Pascoe, Small & Micro Cap, Somaxon Pharmaceuticals Inc., treatment of insomnia, USD
 About QualityStocks (http://QualityStocks.net)
Our name, QualityStocks, emphasizes our commitment to connect subscribers with companies that have huge potential to succeed in the short and long-term future. We believe strong management and vision for the future are crucial for any company to be successful. Timing is everything and we help investors succeed by providing an objective, broad-based view of the SmallCap markets on a daily basis. Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.